The maximal affinity of ligands.
暂无分享,去创建一个
I. Kuntz | P. Kollman | K. Sharp | K. Chen | K. Chen
[1] S. Maestas,et al. The thermodynamics of absorption of xenon by myoglobin. , 1970, The Journal of physical chemistry.
[2] L. Parkhurst. Hemoglobin and Myoglobin Ligand Kinetics , 1979 .
[3] Charles Tanford,et al. The hydrophobic effect , 1980 .
[4] P. Andrews,et al. Functional group contributions to drug-receptor interactions. , 1984, Journal of medicinal chemistry.
[5] J. Schloss. Comparative affinities of the epimeric reaction-intermediate analogs 2- and 4-carboxy-D-arabinitol 1,5-bisphosphate for spinach ribulose 1,5-bisphosphate carboxylase. , 1988, The Journal of biological chemistry.
[6] H. Zollner,et al. Handbook of Enzyme Inhibitors , 1989 .
[7] K A Dill,et al. The meaning of hydrophobicity. , 1990, Science.
[8] P. Bartlett,et al. Synthesis and evaluation of an inhibitor of carboxypeptidase A with a Ki value in the femtomolar range. , 1991, Biochemistry.
[9] J. Knowles,et al. Enzyme catalysis: not different, just better , 1991, Nature.
[10] B Honig,et al. Reconciling the magnitude of the microscopic and macroscopic hydrophobic effects. , 1991, Science.
[11] P A Kollman,et al. Absolute and relative binding free energy calculations of the interaction of biotin and its analogs with streptavidin using molecular dynamics/free energy perturbation approaches , 1993, Proteins.
[12] P A Kollman,et al. What determines the strength of noncovalent association of ligands to proteins in aqueous solution? , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[13] G. Rogers,et al. Kinetic and equilibrium characterization of vesamicol receptor-ligand complexes with picomolar dissociation constants. , 1993, Molecular pharmacology.
[14] J. D. Karkas,et al. Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[15] A. Duranti,et al. 2-Substituted 5-methoxy-N-acyltryptamines: synthesis, binding affinity for the melatonin receptor, and evaluation of the biological activity. , 1993, Journal of medicinal chemistry.
[16] D. Quinn,et al. m-(N,N,N-Trimethylammonio)trifluoroacetophenone: a femtomolar inhibitor of acetylcholinesterase , 1993 .
[17] M Karplus,et al. HOOK: A program for finding novel molecular architectures that satisfy the chemical and steric requirements of a macromolecule binding site , 1994, Proteins.
[18] P. Kollman,et al. A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .
[19] T. Halgren,et al. A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site. , 1995, Journal of medicinal chemistry.
[20] N. Allegretto,et al. Development of potent thrombin receptor antagonist peptides. , 1996, Journal of medicinal chemistry.
[21] E. Shakhnovich,et al. SMoG: de Novo Design Method Based on Simple, Fast, and Accurate Free Energy Estimates. 1. Methodology and Supporting Evidence , 1996 .
[22] William L. Jorgensen,et al. PERFORMANCE OF THE AMBER94, MMFF94, AND OPLS-AA FORCE FIELDS FOR MODELING ORGANIC LIQUIDS , 1996 .
[23] J. C. Dyason,et al. A study of the active site of influenza virus sialidase: an approach to the rational design of novel anti-influenza drugs. , 1996, Journal of medicinal chemistry.
[24] K D Stewart,et al. A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease. , 1996, Journal of medicinal chemistry.
[25] P. Hajduk,et al. Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.
[26] G. Rigdon,et al. Synthesis and evaluation of heterocyclic carboxamides as potential antipsychotic agents. , 1996, Journal of medicinal chemistry.
[27] 5-HT1D receptor agonist properties of novel 2-[5-[[(trifluoromethyl)sulfonyl]oxy]indolyl]ethylamines and their use as synthetic intermediates. , 1996, Journal of medicinal chemistry.
[28] S. Adelstein,et al. [125I/127I]iodoHoechst 33342: synthesis, DNA binding, and biodistribution. , 1996, Journal of medicinal chemistry.
[29] W. Howe,et al. Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors. , 1996, Journal of medicinal chemistry.
[30] New series of potent, orally bioavailable, non-peptidic cyclic sulfones as HIV-1 protease inhibitors. , 1996, Journal of medicinal chemistry.
[31] W J Dunn,et al. Solution of the conformation and alignment tensors for the binding of trimethoprim and its analogs to dihydrofolate reductase: 3D-quantitative structure-activity relationship study using molecular shape analysis, 3-way partial least-squares regression, and 3-way factor analysis. , 1996, Journal of medicinal chemistry.
[32] HIV protease inhibitory bis-benzamide cyclic ureas: a quantitative structure-activity relationship analysis. , 1996, Journal of medicinal chemistry.
[33] Chong-Hwan Chang,et al. Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas. , 1996, Journal of medicinal chemistry.
[34] Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease. , 1996, Journal of medicinal chemistry.
[36] C. E. Peishoff,et al. Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists. , 1996, Journal of medicinal chemistry.
[37] Thomas Lengauer,et al. A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.
[38] P. Pauwels,et al. Serotonin dimers: application of the bivalent ligand approach to the design of new potent and selective 5-HT(1B/1D) agonists. , 1996, Journal of medicinal chemistry.
[39] M. Kuhar,et al. Halogenated mazindol analogs as potential inhibitors of the cocaine binding site at the dopamine transporter. , 1996, Journal of medicinal chemistry.
[40] I D Kuntz,et al. Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsin D. , 1997, Chemistry & biology.
[41] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .
[42] K A Dill,et al. Additivity Principles in Biochemistry* , 1997, The Journal of Biological Chemistry.
[43] Ajay,et al. Can we learn to distinguish between "drug-like" and "nondrug-like" molecules? , 1998, Journal of medicinal chemistry.
[44] Robert M. Stroud,et al. Design of potent selective zinc-mediated serine protease inhibitors , 1998, Nature.
[45] Peter J. Rossky,et al. Surface topography dependence of biomolecular hydrophobic hydration , 1998, Nature.
[46] B Tidor,et al. Computation of electrostatic complements to proteins: A case of charge stabilized binding , 1998, Protein science : a publication of the Protein Society.